{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:43:16Z","timestamp":1784745796621,"version":"3.55.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejps.2023.106678","type":"journal-article","created":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T01:30:38Z","timestamp":1702776638000},"page":"106678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies"],"prefix":"10.1016","volume":"193","author":[{"given":"Lu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106678_bib0097","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41375-020-0920-z","article-title":"The clinical impact of PTPN11 mutations in adults with acute myeloid leukemia","volume":"35","author":"Alfayez","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2023.106678_bib0069","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3892\/ijo.2012.1697","article-title":"Design, synthesis and preclinical evaluation of NRC-AN-019","volume":"42","author":"Amala","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0096","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","article-title":"BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia","volume":"77","author":"Antelope","year":"2019","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejps.2023.106678_bib0082","unstructured":"T. Asaki, Y. Sugiyama, J. Segawa. Amide derivative and medicine. 2010. US7728131B2."},{"key":"10.1016\/j.ejps.2023.106678_bib0110","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0101","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/leu.2012.67","article-title":"SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants","volume":"26","author":"Cao","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2023.106678_bib0087","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejps.2023.106678_bib0054","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood.V104.11.2097.2097","article-title":"Effects of adaphostin, a novel tyrphostin inhibitor, in diverse models of imatinib mesylate resistance","volume":"104","author":"Chandra","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0105","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0076","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12032-016-0758-4","article-title":"Multi-kinase inhibitors, AURKs and cancer","volume":"33","author":"Cicenas","year":"2016","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0109","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0063","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF-1R\/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0032","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0005","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0089","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2016.152710","article-title":"Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia","volume":"102","author":"Cortes","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ejps.2023.106678_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0099","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-139847","article-title":"Phase 1 trial of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): activity in CML chronic phase patients failing TKI therapies including ponatinib","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0080","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1200\/jco.2007.25.18_suppl.7046","article-title":"A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib","volume":"25","author":"Craig","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0043","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","article-title":"Asciminib: first approval","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2023.106678_bib0002","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0049","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2023.106678_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202307898","article-title":"Transient transcription machineries modulate dynamic functions of g-quadruplexes: temporal regulation of biocatalytic circuits, gene replication and transcription","volume":"62","author":"Dong","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejps.2023.106678_bib0001","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0029","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620717719851","article-title":"Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update","volume":"8","author":"Eskazan","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejps.2023.106678_bib0061","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejps.2023.106678_bib0092","unstructured":"D.L. Flynn, P.A. Petillo, M.D. Kaufman. Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases. 2013. WO2013036232A2."},{"key":"10.1016\/j.ejps.2023.106678_bib0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clml.2013.11.001","article-title":"A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed\/refractory leukemia or myelofibrosis","volume":"14","author":"Foran","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejps.2023.106678_bib0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejps.2023.106678_bib0077","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2023.106678_bib0017","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejps.2023.106678_bib0078","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1111\/bph.12750","article-title":"The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo","volume":"171","author":"Grace","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106678_bib0068","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1021\/op400137m","article-title":"Process development and multikilogram syntheses of XL228 utilizing a regioselective isoxazole formation and a selective SNAr reaction to a pyrimidine core","volume":"17","author":"Guz","year":"2013","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejps.2023.106678_bib0088","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-17-0241","article-title":"The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors","volume":"16","author":"Harney","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejps.2023.106678_bib0016","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cncr.20752","article-title":"New approaches in the treatment of myelofibrosis","volume":"103","author":"Hennessy","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2023.106678_bib0007","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0072","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/jm800984v","article-title":"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity","volume":"52","author":"Howard","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2023.106678_bib0006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting Bcr-Abl transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0103","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0014","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2023.106678_bib0094","first-page":"289","article-title":"PF\u2011114, a novel selective inhibitor of BCR\u2011ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells","volume":"55","author":"Ivanova","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0091","article-title":"Open-label, multicenter, phase 1b\/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer","volume":"37","author":"Janku","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0041","first-page":"13","article-title":"Clinical efficacy and safety of flumatinib in newly diagnosed chronic myelogenous leukemia","volume":"78","author":"Jiang","year":"2023","journal-title":"Pharmazi"},{"key":"10.1016\/j.ejps.2023.106678_bib0051","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-142142","article-title":"Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase II) trials","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0048","doi-asserted-by":"crossref","first-page":"14932","DOI":"10.1021\/jacs.3c04640","article-title":"Acetylation targeting chimera enables acetylation of the tumor suppressor p53","volume":"145","author":"Kabir","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2023.106678_bib0079","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1002\/cncr.25281","article-title":"Questions regarding frontline therapy of acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2023.106678_bib0019","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd2135","article-title":"Dasatinib","volume":"5","author":"Kantarjian","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2023.106678_bib0081","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","article-title":"Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2023.106678_bib0036","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0030","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejps.2023.106678_bib0071","first-page":"1442","article-title":"AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer","volume":"11","author":"Kimura","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejps.2023.106678_bib0070","unstructured":"A.K. Kompella, B.R. Adibhatla Kali Satya, S. Rachakonda, N. Venkaiah Chowdary. Crystal form of phenylamino pyrimidine derivatives. 2011. US8067422B2."},{"key":"10.1016\/j.ejps.2023.106678_bib0018","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/op300212u","article-title":"A facile total synthesis for large-scale production of imatinib base","volume":"16","author":"Kompella","year":"2012","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejps.2023.106678_bib0042","doi-asserted-by":"crossref","first-page":"15488","DOI":"10.1021\/jacs.3c04130","article-title":"Living Suzuki\u2013Miyaura catalyst-transfer polymerization for precision synthesis of length-controlled armchair graphene nanoribbons and their block copolymers","volume":"145","author":"Lee","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2023.106678_bib0056","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00280-005-0094-4","article-title":"Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr\/abl","volume":"57","author":"Li","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106678_bib0028","article-title":"Low catalyst loading enhances charge accumulation for photoelectrochemical water splitting","volume":"62","author":"Liu","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejps.2023.106678_bib0020","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.ejps.2023.106678_bib0047","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00277-022-04932-6","article-title":"Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia","volume":"101","author":"Luna","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejps.2023.106678_bib0040","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/leu.2010.169","article-title":"HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance","volume":"24","author":"Luo","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2023.106678_bib0067","first-page":"111","article-title":"Novel agents on the horizon for cancer therapy","volume":"59","author":"Ma","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejps.2023.106678_bib0108","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.ejps.2023.106678_bib0098","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2021.1990034","article-title":"Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"14","author":"Malik","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ejps.2023.106678_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2023.106678_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejps.2023.106678_bib0013","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2023.106678_bib0093","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/leu.2014.326","article-title":"PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation","volume":"29","author":"Mian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2023.106678_bib0074","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1078-0432.CCR-14-1592","article-title":"A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a cancer research UK study","volume":"21","author":"Moreno","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2023.106678_bib0104","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2007.09.005","article-title":"Aurora kinases as targets for cancer therapy","volume":"34","author":"Mountzios","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejps.2023.106678_bib0058","unstructured":"V.L. Narayanan, E.A. Sausville, G. Kaur, R.K. Varma. Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs. 2005. US6943191B1."},{"key":"10.1016\/j.ejps.2023.106678_bib0064","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2174\/156802608784911635","article-title":"Inhibitors of ABL and the ABL-T315I mutation","volume":"8","author":"Noronha","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejps.2023.106678_bib0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/CAD.0b013e3281721ff6","article-title":"Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells","volume":"18","author":"Nowak","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejps.2023.106678_bib0003","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0008","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2023.106678_bib0086","unstructured":"Y. Ohta, F. Kanai, S. Nara, Y. Kanda, H. Umehara, Y. Shiotsu, T. Naoe, H. Kiyoi, K. Kawashima, H. Ando, M. Miyama. Indazole derivatives. 2011. US7919517B2."},{"key":"10.1016\/j.ejps.2023.106678_bib0062","unstructured":"P. Ple. Quinazoline derivatives as src tyrosine kinase inhibitors. 2004. WO2004041829A1."},{"key":"10.1016\/j.ejps.2023.106678_bib0084","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1182\/blood-2008-09-177030","article-title":"A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response","volume":"113","author":"Pratz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0073","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/ijc.26324","article-title":"AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas","volume":"130","author":"Qi","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejps.2023.106678_bib0052","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2021-153937","article-title":"Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I-mutated chronic-and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP)","volume":"138","author":"Qian","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0053","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2021-153065","article-title":"Updated safety and efficacy results of phase 1 study of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML)","volume":"138","author":"Qian","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0010","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0046","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0033","first-page":"57","article-title":"Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia","volume":"6","author":"Rassi","year":"2013","journal-title":"Pharmgenom. Pers. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0034","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2023.106678_bib0011","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2023.106678_bib0027","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2217\/fon-2018-0468","article-title":"Nilotinib in the treatment of chronic myeloid leukemia","volume":"15","author":"Sacha","year":"2019","journal-title":"Futur. Oncol"},{"key":"10.1016\/j.ejps.2023.106678_bib0026","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0107","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66","author":"Samanta","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2023.106678_bib0023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V106.11.38.38","article-title":"Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a phase I study","volume":"106","author":"Sawyers","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0012","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0100","unstructured":"P. Sengupta, H.A. Chokshi, C.S. Puri, S.Y. Chimanwala, V.A. Mehta, D.M. Desai, T.R. Chitturi, R. Thennati, J.D.M. Atkinson. Diarylacetylene hydrazide containing tyrosine kinase inhibitors. 2012. WO2012098416A1."},{"key":"10.1016\/j.ejps.2023.106678_bib0066","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood.V110.11.474.474","article-title":"Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228","volume":"110","author":"Shah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0085","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood.V110.11.1832.1832","article-title":"KW-2449, a novel multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora, suppresses the growth of aml both in vitro and in vivo","volume":"110","author":"Shiotsu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0083","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2009-01-199307","article-title":"KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR\/ABL translocation","volume":"114","author":"Shiotsu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0009","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0057","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-07-0025","article-title":"Proteomic analysis identifies oxidative stress induction by adaphostin","volume":"13","author":"Stockwin","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2023.106678_bib0022","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2023.106678_bib0106","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2023.106678_bib0021","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2023.106678_bib0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2666","article-title":"An open label, multicenter, phase 1b\/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors","volume":"37","author":"Tolcher","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2023.106678_bib0095","unstructured":"H. Wan, C. Li, C. Shi, H. Liu, P. Li. Anti-tumor activity with acetylene derivatives. 2013. WO2013170774A1."},{"key":"10.1016\/j.ejps.2023.106678_bib0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of Bcr-Abl for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2023.106678_bib0059","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bjc.2017.484","article-title":"A first-in-human phase I study to determine the maximum tolerated dose of the oral Src\/ABL inhibitor AZD0424","volume":"118","author":"Woodcock","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejps.2023.106678_bib0044","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2023.106678_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202307895","article-title":"Improved birefringence activated by tetrahedra decorated with single linear unit","volume":"62","author":"Xie","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejps.2023.106678_bib0102","unstructured":"S. Yang, Y. Wei. Arylamino purine derivatives, preparation method and pharmaceutical use thereof. 2015. US9096601B2."},{"key":"10.1016\/j.ejps.2023.106678_bib0038","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.3390\/molecules15064261","article-title":"Synthesis of bosutinib from 3-methoxy-4-hydroxybenzoic acid","volume":"15","author":"Yin","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2023.106678_bib0039","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multi-center FESTnd study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723003068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723003068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:08:31Z","timestamp":1760530111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723003068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":110,"alternative-id":["S0928098723003068"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106678","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106678"}}